@article {1291,
	title = {Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors},
	journal = {Pediatr Blood Cancer},
	volume = {46},
	year = {2006},
	note = {Pulsipher, Michael A Nagler, Arnon Iannone, Robert Nelson, Robert M Review United States Pediatric blood \& cancer Pediatr Blood Cancer. 2006 Apr;46(4):422-33.},
	month = {Apr},
	pages = {422 - 33},
	edition = {38735},
	abstract = {BACKGROUND: Granulocyte colony stimulating factor (G-CSF) is used for collection of hematopoietic cells in most adult and a smaller but significant percentage of pediatric normal donor harvests. Short and long-term risks of G-CSF administration and leukopheresis are not well understood in the pediatric population. PROCEDURE: Literature review including observations from the IBMTR, NMDP, EBMT, German Donor Registry, and the authors{\textquoteright} work. RESULTS: G-CSF causes temporary discomfort in a minority of younger donors. Rare serious side effects of G-CSF have yet to be reported in children. To date, an increase in hematological malignancies after short-term G-CSF use has not been detected in adult donors and no cases have been reported in children. Reported complications of leukopheresis in children are rare and minor, but donors <20 kg may be exposed to allogeneic blood products. Pediatric aged donors vary widely in their ability to assent or consent to the risks of a donation procedure. There are key regulations and ethical imperitives, which must be addressed in deciding which donation procedures are appropriate for minors. CONCLUSIONS: While short term administration of G-CSF and leukopheresis appear to be safe and effective procedures when used to assist in collection of a hematopoietic cell graft from a normal pediatric donor, institutions adding or substituting one or both of these procedures for standard marrow donation must decide whether the donor should be considered a research subject, and if so, whether the new procedures are a minor increase over minimal risk. Because these procedures are being performed on and off study at many pediatric centers, a comprehensive study addressing donor safety could help clarify risks of rare adverse events.},
	keywords = {*Bone Marrow Transplantation / ethics / standards, *Hematopoietic Stem Cell Mobilization / ethics / standards, *Hematopoietic Stem Cell Transplantation / ethics / standards, *Leukapheresis / ethics / standards, *Tissue Donors / classification / ethics, Child, effects, Granulocyte Colony-Stimulating Factor / *administration \& dosage / adverse, Humans, Risk Assessment, Risk Factors, Safety},
	issn = {1545-5009 (Print) 1545-5009 (Linking)},
	doi = {10.1002/pbc.20708},
	author = {Pulsipher,M. A. and Nagler,A. and Iannone,R. and Nelson,R. M.}
}
